Insmed Inc (INSM) Stock Price, Quote & News

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor o...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 977 9900

Website: www.insmed.com

Address:

700 US Highway 202/206, Bridgewater, United States

pianoman439 May. 8 at 9:57 PM

$INSM I’m in the position to double down, and I’m seriously considering it. Insmed is literally growing exponentially with a train of opportunities following behind. I do want to see insider buying to support my thesis.

2 · Reply

JasonCO May. 8 at 4:57 PM

$INSM all gaps get filled

1 · Reply

Subie5729 May. 8 at 2:24 PM

$INSM i applied to this company multiple times, never got a response no wonder they flopped 20%

0 · Reply

Dy2ski May. 7 at 10:04 PM

$INSM Congratulations to those that have been short and to the longs who have been selling into this stocks heavy downtrend the last several months. Tip of the hat. 👌 Perhaps CEO Lewis can stop dumping shares now and find us a buyer above$150. There is A LOT riding on that OLE read-out for TPIP in Q3 now, especially after the 2 Brensocatib flops recently. Unreal.

2 · Reply

JoeB07 May. 7 at 7:42 PM

$MDGL I guess it’s all relative. At least you’re not $INSM which is now 50% off its highs from last year… or $ADMA which is more than a total disaster and under a violent short attack.

1 · Reply

JuggernautRaider May. 7 at 6:32 PM

$INSM woah what happened

0 · Reply

JoeB07 May. 7 at 6:14 PM

$INSM what a disaster. So sorry for long term holders. What a mess.

0 · Reply

Nakom May. 7 at 4:46 PM

$INSM Stock still way over valued. Need to see it drop another $20 before it hits a good entry point.

0 · Reply

he123 May. 7 at 4:44 PM

$INSM there could be some short coverage and pop , but overall long bullish

0 · Reply

Olivia_Strickland May. 7 at 4:24 PM

$INSM in zero so far but eyes glued to 105, that's where I want to see it base before I'd even nibble. Q1 missed and the launch narrative cracked, tape gave it a 22% haircut on 4x avg vol so the panic flush is doing real work. Sitting half off the 52w high now which is the kind of reset that either bounces hard or grinds for weeks. what level are you guys watching for a reclaim, or is this still falling-knife territory?

2 · Reply

Insmed earnings selloff a buying opportunity, says H.C. Wainwright

2026-05-08T15:16:18.000Z - 2 days ago

Insmed price target lowered to $185 from $200 at Raymond James

2026-05-08T13:36:14.000Z - 2 days ago

Insmed price target lowered to $226 from $230 at Guggenheim

2026-05-08T12:09:40.000Z - 2 days ago

Insmed price target lowered to $160 from $177 at Wells Fargo

2026-05-07T21:52:34.000Z - 3 days ago

Insmed pullback a buying opportunity, says Roth Capital

2026-05-07T14:20:21.000Z - 3 days ago

Insmed reports Q1 EPS (76c), consensus ($1.00)

May 7, 2026, 8:00 AM EDT - 3 days ago

Insmed Earnings Call Transcript: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 days ago

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:30 PM EDT - 4 days ago

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

May 4, 2026, 7:00 AM EDT - 6 days ago

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

2026-05-04T10:40:53.000Z - 6 days ago

Insmed price target raised to $214 from $212 at BofA

Apr 30, 2026, 7:00 AM EDT - 10 days ago

Insmed to Present at May 2026 Investor Conferences

Apr 23, 2026, 7:00 AM EDT - 17 days ago

Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026

Apr 7, 2026, 4:32 PM EDT - 4 weeks ago

Insmed discontinues development of skin condition drug after mid-stage study miss

Apr 7, 2026, 4:01 PM EDT - 4 weeks ago

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Mar 23, 2026, 8:00 AM EDT - 6 weeks ago

Insmed Transcript: Study result

Mar 23, 2026, 7:00 AM EDT - 6 weeks ago

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Insmed Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 7:00 AM EST - 2 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 2, 2026, 9:50 AM EST - 2 months ago

Insmed Transcript: TD Cowen 46th Annual Health Care Conference

Feb 19, 2026, 8:00 AM EST - 2 months ago

Insmed Earnings Call Transcript: Q4 2025

Feb 19, 2026, 7:00 AM EST - 2 months ago

Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

Feb 13, 2026, 7:00 AM EST - 3 months ago

Insmed To Present at March 2026 Investor Conferences

Feb 5, 2026, 7:00 AM EST - 3 months ago

Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

Jan 28, 2026, 7:00 AM EST - 3 months ago

Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

Jan 12, 2026, 6:14 PM EST - 4 months ago

Insmed CEO Will Lewis talks its rare disease drug pipeline

Jan 12, 2026, 6:00 PM EST - 4 months ago

Insmed Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 7:00 AM EST - 4 months ago

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 7:00 AM EST - 4 months ago

Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 6:09 PM EST - 5 months ago

Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news

Dec 18, 2025, 7:12 AM EST - 5 months ago

Insmed Stock Plummets 19%. This Is What Sparked the Selloff.

Dec 17, 2025, 5:35 PM EST - 5 months ago

Insmed scraps development of sinus drug after mid-stage study failure

Dec 17, 2025, 4:01 PM EST - 5 months ago

Insmed Provides Clinical and Business Update

Dec 11, 2025, 10:37 AM EST - 5 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND MASI NTRA PODD UNH WGS

Dec 2, 2025, 11:15 AM EST - 5 months ago

Insmed Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 3:45 PM EST - 6 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH LITE MP MU

Nov 18, 2025, 11:00 AM EST - 6 months ago

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Nov 18, 2025, 3:30 AM EST - 6 months ago

Insmed Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 7:00 AM EST - 6 months ago

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

Nov 5, 2025, 7:00 AM EST - 6 months ago

Insmed To Present at November and December 2025 Investor Conferences

Nov 3, 2025, 6:13 PM EST - 6 months ago

Latest read on rare disease gene therapy from Insmed CEO Will Lewis

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Insmed Earnings Call Transcript: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 4:05 PM EDT - 7 months ago

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

Oct 17, 2025, 7:00 AM EDT - 7 months ago

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Oct 16, 2025, 7:00 AM EDT - 7 months ago

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Oct 15, 2025, 7:00 AM EDT - 7 months ago

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

Sep 22, 2025, 7:00 AM EDT - 8 months ago

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Sep 9, 2025, 4:50 PM EDT - 8 months ago

Insmed Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 5, 2025, 8:00 AM EDT - 8 months ago

Insmed Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 21, 2025, 7:00 AM EDT - 9 months ago

Insmed To Present at September Investor Conferences

Aug 19, 2025, 1:04 PM EDT - 9 months ago

Josh Brown's Best Stocks in the Market: Insmed

Aug 13, 2025, 6:15 PM EDT - 9 months ago

Insmed CEO on what's next for company after FDA greenlights lung disease drug

Aug 12, 2025, 12:00 PM EDT - 9 months ago

Insmed Transcript: FDA Announcement

Aug 12, 2025, 11:42 AM EDT - 9 months ago

US FDA approves Insmed's lung disease drug

Aug 12, 2025, 11:34 AM EDT - 9 months ago

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Insmed Earnings Call Transcript: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 9 months ago

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 12:37 PM EDT - 10 months ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN BBIO

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

Jul 7, 2025, 6:29 PM EDT - 10 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO BMRN GILD XBI

Jun 16, 2025, 5:05 AM EDT - 11 months ago

Is Insmed Stock Overvalued After The 45% Jump?

Jun 11, 2025, 10:25 PM EDT - 11 months ago

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Jun 11, 2025, 4:01 PM EDT - 11 months ago

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Jun 11, 2025, 9:20 AM EDT - 11 months ago

Insmed Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 5:56 PM EDT - 11 months ago

Insmed CEO Will Lewis on stock surge after positive trial results

Jun 10, 2025, 8:00 AM EDT - 11 months ago

Insmed Transcript: Study Update

Jun 10, 2025, 7:25 AM EDT - 11 months ago

Insmed's blood pressure drug meets main goal in mid-stage trial

Jun 10, 2025, 7:00 AM EDT - 11 months ago

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

LEGN VRNA

pianoman439 May. 8 at 9:57 PM

2 · Reply

JasonCO May. 8 at 4:57 PM

$INSM all gaps get filled

1 · Reply

Subie5729 May. 8 at 2:24 PM

$INSM i applied to this company multiple times, never got a response no wonder they flopped 20%

0 · Reply

Dy2ski May. 7 at 10:04 PM

2 · Reply

JoeB07 May. 7 at 7:42 PM

$MDGL I guess it’s all relative. At least you’re not $INSM which is now 50% off its highs from last year… or $ADMA which is more than a total disaster and under a violent short attack.

1 · Reply

JuggernautRaider May. 7 at 6:32 PM

$INSM woah what happened

0 · Reply

JoeB07 May. 7 at 6:14 PM

$INSM what a disaster. So sorry for long term holders. What a mess.

0 · Reply

Nakom May. 7 at 4:46 PM

$INSM Stock still way over valued. Need to see it drop another $20 before it hits a good entry point.

0 · Reply

he123 May. 7 at 4:44 PM

$INSM there could be some short coverage and pop , but overall long bullish

0 · Reply

Olivia_Strickland May. 7 at 4:24 PM

2 · Reply

Sillyspuh May. 7 at 4:15 PM

$INSM Wow, didn't see that coming.

0 · Reply

cruyff73 May. 7 at 4:13 PM

$INSM I've seen manipulation before but this is insane. Quite literally no logical explanation for a 20% drop.

2 · Reply

Randy_Lahey_Trevor_Corey May. 7 at 4:02 PM

$INSM bring on 99

0 · Reply

Randy_Lahey_Trevor_Corey May. 7 at 3:47 PM

$INSM lol wild

1 · Reply

chartistmind May. 7 at 3:39 PM

$FSLY $ZTS $PLNT $SHAK $INSM market is pissed

0 · Reply

WAJeff May. 7 at 3:27 PM

$INSM Pros: Sold most of it above $200 Cons: Still had some from $140 level that I didn’t sell. See gaps at $98/$81 so I’m not eager to avg down yet either. How are you guys approaching this one?

4 · Reply

Nakom May. 7 at 3:22 PM

$INSM To large of float and way to much debt. Very easy to manipulate. Will be the new stock to short.

0 · Reply

Nakom May. 7 at 3:19 PM

$INSM Stock is way over valued.

0 · Reply

Kepnauclair May. 7 at 2:22 PM

$INSM Fickle investors wanting blowout earnings reports with revised upward guidance are part of investing. It seems the company met or exceeded all guidance, and its stock is getting clobbered. For long-term investors, this is part of the deal. If you believe in the company’s prospects and pipeline and the management team, the stock price fluctuation is just noise. There appears to be a high probability that there will be a merger or buyout of this company, although it would be nice to see them make it go of it on their own. Patient investors will reap the rewards.

0 · Reply

cruyff73 May. 7 at 2:19 PM

$INSM what a bizarre reaction

0 · Reply

kelrock90 May. 7 at 1:24 PM

$INSM Thoughts on where SP is headed today?

1 · Reply

pianoman439 May. 7 at 1:09 PM

$INSM Lewis: “…let me be explicit. We are in a fantastic spot!”

1 · Reply

Market Cap	21.88B
Revenue (ttm)	606.42M
Net Income (ttm)	-1.28B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-210.54%
Debt to Equity Ratio	0.73

Volume	8,588,199
Avg Vol	2,504,808
Day's Range	N/A - N/A
Shares Out	215.85M
Stochastic %K	5%
Beta	0.89
Analysts	Strong Sell
Price Target	$212.67